| 1. |
Heparin in acute stroke: the controversy continues |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1377,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
UK NICE issues guidance on vaginal tape, antivirals, insulin |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1377,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
Anti-inflammatories in heart failure explored |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1377,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Hormonal contraception use: no effect on HIV-1 acquisition |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1377,
2003,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
Unnecessary healthcare service and antibacterial use is high among paediatric patients with upper respiratory tract infections |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1377,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
Bevacizumab boosts chemotherapy response in breast cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1377,
2003,
Page 7-8
RH Carlson,
Preview
|
|
摘要:
Vascular endothelial growth factor (VEGF) is known to stimulate the process of angiogenesis; the humanised monoclonal antibody bevacizumab ['Avastin'] is one of the first agents designed to block the actions of VEGF in order to prevent malignant tumour growth. Preclinical data have shown that combining bevacizumab with standard chemotherapy agents including paclitaxel, fluorouracil and capecitabine enhances their anticancer efficacy. The bevacizumab-chemotherapy combination is currently being evaluated in treatment of several cancers including metastatic and inflammatory breast cancers, mesothelioma, colorectal, ovarian and renal cell carcinoma, among others. Results from a phase III study of bevacizumab in combination with capecitabine in patients with advanced breast cancer were presented at the 25th annual San Antonio Breast Cancer Symposium [San Antonio, US; December 2002].Although the primary endpoint, the time to disease progression, was not significantly improved, the bevacizumab/capecitabine combination did increase the response rate. This points to a proof-of-principle for combining antiangiogenesis therapy with chemotherapy in advanced breast cancer treatment, said Dr Kathy Miller from Indiana University School of Medicine in Indianapolis, US. Another study presented at the meeting suggested possible benefits in combining bevacizumab with vinorelbine.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
The anti-obesity drug AOD-9604*has demonstrated favourable safety and tolerability in a phase II clinical trial. |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1377,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
The HIV-gp120 vaccine ['Aidsvax']*failed to show overall efficacy, but may be effective in certain ethnic groups, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1377,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
News from the 44th Annual Meeting of the American Society of Hematology |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1377,
2003,
Page 10-12
RM Poole,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
Oral ganciclovir is more effective than oral aciclovir for long-term prophylaxis of cytomegalovirus (CMV) disease |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1377,
2003,
Page 13-13
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
